GHK-Cu vs Acetyl octapeptide-3
Separate topical human data, mechanism and formulation; avoid treating all cosmetic peptides as interchangeable.
| Attribute | GHK-Cu | Acetyl octapeptide-3 |
|---|---|---|
| Human evidence | Human evidence is route-specific and mixed. A randomized venous-ulcer study of topical 0.4% copper-tripeptide cream found no superiority over vehicle, and a 13-person randomized post-CO2-laser study found no significant objective skin benefit, although subjective satisfaction favored treatment. Injectable/systemic evidence remains much weaker. | Human cosmetic studies of microneedle formulations containing acetyl octapeptide-3 report wrinkle/skin-quality improvements, but the studied products also contained other active ingredients. |
| Research focus | Skin, wound healing, collagen, hair/cosmetic research | Topical cosmetic wrinkle research |
| Regulatory status | Injectable GHK-Cu is not an FDA-approved therapeutic product; FDA highlights compounded-injection safety uncertainty. | Cosmetic ingredient rather than an approved injectable therapeutic. |
| Route / formulation | Topical cosmetic evidence cannot be automatically extrapolated to injected GHK-Cu. | Product-level effects from multi-active microneedle formulations cannot be attributed wholly to acetyl octapeptide-3. |
Why these are compared
These compounds appear in the skin / appearance research evidence landscape, but they are not interchangeable. GHK-Cu is copper-binding tripeptide complex studied in skin, wound healing, collagen, hair/cosmetic research; Acetyl octapeptide-3 is synthetic cosmetic octapeptide studied in topical cosmetic wrinkle research. The purpose of this page is to compare the evidence base, not to recommend one compound over another.
Evidence maturity
GHK-Cu: Topical/cosmetic human evidence is limited and mixed; injectable evidence limited.
Acetyl octapeptide-3: Small human cosmetic formulation-level evidence; isolated ingredient effect not established.
The table above gives the fuller human-evidence, regulatory and formulation context. Open the individual profiles for study-level records, limitations and source provenance.
What this comparison can and cannot establish
No head-to-head clinical evidence identified. Cross-study comparisons can be distorted by differences in population, route, formulation, dose, duration and endpoint. WhichPeps therefore does not turn indirect comparisons into a treatment recommendation or name a winner. A well-designed head-to-head human trial using comparable populations and clinically relevant outcomes would reduce uncertainty.